Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
CLINICAL CANCER RESEARCH（2019）
Key words
Tumor Regression
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined